Enovis (C520) Stock Forecast, Price Targets and Analysts Predictions

C520 Analyst Ratings

Strong Buy

11 Buy

1 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Enovis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

C520 Stock 12 Month Forecast

Average Price Target

―

Based on 12 Wall Street analysts offering 12 month price targets for Enovis in the last 3 months. The average price target is CHF32.15 with a high forecast of CHF43.07 and a low forecast of CHF22.36. The average price target represents a ― change from the last price of ―.

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

Highest Price TargetCHF43.07

Average Price TargetCHF32.15

Lowest Price TargetCHF22.36

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Larry Biegelsen

Wells Fargo

CHF27.33

Buy

―

Reiterated

09/08/26

Wells Fargo Remains a Buy on Enovis (ENOV)

David Turkaly

Citizens JMP

CHF45.55→CHF38.93

Buy

―

Reiterated

09/02/26

Enovis price target lowered to $47 from $55 at CitizensEnovis price target lowered to $47 from $55 at Citizens

Michael Matson

Needham

CHF43.07

Buy

―

Reiterated

09/01/26

Analyst Reiterates Buy on Enovis, Maintains $52 Price Target Following Strategic eCential Robotics Acquisition

Caitlin Roberts

Canaccord Genuity

CHF37.27

Buy

―

Reiterated

09/01/26

Canaccord Genuity Remains a Buy on Enovis (ENOV)

Ryan Zimmerman

BTIG

CHF32.3→CHF29.82

Buy

―

Reiterated

09/01/26

Enovis: Buy Rating Reaffirmed as Surgical Robotics Acquisition Closes Competitive Gap; Price Target Trimmed to $36 on Deal-Related Costs and Leverage

Keith Hinton

Freedom Capital Markets

CHF33.96→CHF29.82

Buy

―

Reiterated

09/01/26

We like the deal longer-term and maintain our Buy rating, but we lower our price target to $36 (from $41) based on ~8.0x 2027E EBITDA.

Vik Chopra

BMO Capital

CHF24.85→CHF22.36

Buy

―

Assigned

09/01/26

Enovis price target lowered to $27 from $30 at BMO CapitalEnovis price target lowered to $27 from $30 at BMO Capital

Steven Lichtman

William Blair

―

Buy

―

Reiterated

08/14/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Enovis (NYSE: ENOV) and Lantheus (NASDAQ: LNTH)

Robbie Marcus

J.P. Morgan

CHF23.19

Hold

―

Reiterated

08/10/26

J.P. Morgan Sticks to Its Hold Rating for Enovis (ENOV)

Vijay Kumar

Evercore ISI

CHF26.5

Buy

―

Reiterated

08/07/26

Evercore ISI Sticks to Their Buy Rating for Enovis (ENOV)

Patrick Wood

UBS

CHF41.41→CHF42.24

Buy

―

Initiated

07/28/26

Enovis assumed with a Buy at UBSEnovis assumed with a Buy at UBS

Rong Li

Jefferies

CHF33.13

Buy

―

Reiterated

07/14/26

Enovis (ENOV) Receives a Buy from Jefferies

Jeff Johnson

Robert W. Baird

CHF37.27→CHF30.65

Buy

―

Reiterated

05/08/26

Enovis price target lowered to $37 from $45 at BairdEnovis price target lowered to $37 from $45 at Baird

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Larry Biegelsen

Wells Fargo

CHF27.33

Buy

―

Reiterated

09/08/26

Wells Fargo Remains a Buy on Enovis (ENOV)

David Turkaly

Citizens JMP

CHF45.55→CHF38.93

Buy

―

Reiterated

09/02/26

Enovis price target lowered to $47 from $55 at CitizensEnovis price target lowered to $47 from $55 at Citizens

Michael Matson

Needham

CHF43.07

Buy

―

Reiterated

09/01/26

Analyst Reiterates Buy on Enovis, Maintains $52 Price Target Following Strategic eCential Robotics Acquisition

Caitlin Roberts

Canaccord Genuity

CHF37.27

Buy

―

Reiterated

09/01/26

Canaccord Genuity Remains a Buy on Enovis (ENOV)

Ryan Zimmerman

BTIG

CHF32.3→CHF29.82

Buy

―

Reiterated

09/01/26

Enovis: Buy Rating Reaffirmed as Surgical Robotics Acquisition Closes Competitive Gap; Price Target Trimmed to $36 on Deal-Related Costs and Leverage

Keith Hinton

Freedom Capital Markets

CHF33.96→CHF29.82

Buy

―

Reiterated

09/01/26

We like the deal longer-term and maintain our Buy rating, but we lower our price target to $36 (from $41) based on ~8.0x 2027E EBITDA.

Vik Chopra

BMO Capital

CHF24.85→CHF22.36

Buy

―

Assigned

09/01/26

Enovis price target lowered to $27 from $30 at BMO CapitalEnovis price target lowered to $27 from $30 at BMO Capital

Steven Lichtman

William Blair

―

Buy

―

Reiterated

08/14/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Enovis (NYSE: ENOV) and Lantheus (NASDAQ: LNTH)

Robbie Marcus

J.P. Morgan

CHF23.19

Hold

―

Reiterated

08/10/26

J.P. Morgan Sticks to Its Hold Rating for Enovis (ENOV)

Vijay Kumar

Evercore ISI

CHF26.5

Buy

―

Reiterated

08/07/26

Evercore ISI Sticks to Their Buy Rating for Enovis (ENOV)

Patrick Wood

UBS

CHF41.41→CHF42.24

Buy

―

Initiated

07/28/26

Enovis assumed with a Buy at UBSEnovis assumed with a Buy at UBS

Rong Li

Jefferies

CHF33.13

Buy

―

Reiterated

07/14/26

Enovis (ENOV) Receives a Buy from Jefferies

Jeff Johnson

Robert W. Baird

CHF37.27→CHF30.65

Buy

―

Reiterated

05/08/26

Enovis price target lowered to $37 from $45 at BairdEnovis price target lowered to $37 from $45 at Baird

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

OMCLOmnicell

KNSAKiniksa Pharmaceuticals

ACHVAchieve Life Sciences

AHCOAdaptHealth

ZVRAZevra Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Enovis

3 Months

Jeff JohnsonRobert W. Baird

Success Rate

6/15 ratings generated profit

Average Return

-2.19%

Copying Jeff Johnson's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -2.19% per trade.

1 Year

Vijay KumarEvercore ISI

Success Rate

2/14 ratings generated profit

Average Return

-21.04%

Copying Vijay Kumar's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -21.04% per trade.

2 Years

Vijay KumarEvercore ISI

Success Rate

0/14 ratings generated profit

Average Return

-34.78%

Copying Vijay Kumar's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -34.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

C520 Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

10

9

7

13

Buy

4

5

7

8

Hold

0

1

Sell

0

Strong Sell

0

total

14

13

14

15

22

In the current month, C520 has received 21 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. C520 average Analyst price target in the past 3 months is 32.15.

Each month's total comprises the sum of three months' worth of ratings.

C520 Financial Forecast

C520 Earnings Forecast

Next quarter’s earnings estimate for C520 is CHF0.65 with a range of CHF0.62 to CHF0.69. The previous quarter’s EPS was CHF0.75. C520 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year C520 has Performed in-line its overall industry.

C520 Sales Forecast

Next quarter’s sales forecast for C520 is CHF466.26M with a range of CHF461.92M to CHF470.90M. The previous quarter’s sales results were CHF487.44M. C520 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year C520 has Performed in-line its overall industry.

C520 Stock Forecast FAQ

What is CH:C520’s average 12-month price target, according to analysts?

Based on analyst ratings, Enovis’s 12-month average price target is 32.15.

What is CH:C520’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for CH:C520, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Enovis a Buy, Sell or Hold?

Enovis has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.

What is Enovis’s share price target?

The average share price target for Enovis is 32.15. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF43.07 ,and the lowest forecast is CHF22.36. The average share price target represents N/A Increase from the current price of N/A.

What do analysts say about Enovis?

Enovis’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Enovis?

To buy shares of CH:C520, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Enovis (C520) Stock Forecast & Price Target

C520 Analyst Ratings

C520 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Enovis

C520 Analyst Recommendation Trends

C520 Financial Forecast

C520 Earnings Forecast

C520 Sales Forecast

C520 Stock Forecast FAQ

Detailed List of Analyst Forecasts